Does lower limb amputation concern all SGLT2 inhibitors?

Sodium–glucose cotransporter 2 (SGLT2) inhibitors showed cardiorenal protection in patients with diabetes mellitus and cardiovascular disease. However, increase in lower limb amputation with canagliflozin, but not empagliflozin, was reported. The reason for this adverse effect remains speculative and whether it concerns all SGLT2 inhibitors is controversial.